All Stories

  1. Exercise Prescription in Cardio-Oncology
  2. Genetic Background in Patients with Cancer Therapy-Induced Cardiomyopathy
  3. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond
  4. Gender Effect on Clinical Profiles, Pharmacological Treatments and Prognosis in Patients Hospitalized for Heart Failure
  5. Right Ventricular Subclinical Dysfunction in SLE Patients Correlates with Metabolomic Fingerprint and Organ Damage
  6. Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors
  7. Metabolomic Profiles on Antiblastic Cardiotoxicity: New Perspectives for Early Diagnosis and Cardioprotection
  8. Cardiovascular Risk Perception and Knowledge among Italian Women: Lessons from IGENDA Protocol
  9. Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study
  10. To be or not to be resilient in familial hypercholesterolaemia: implications for the management
  11. Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
  12. Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC)
  13. Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
  14. Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway
  15. Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry
  16. Early ischemia identification employing 2D speckle tracking selective layers analysis during dobutamine stress echocardiography
  17. Metabolomic Perspectives in Antiblastic Cardiotoxicity and Cardioprotection
  18. Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
  19. Acute heart failure congestion and perfusion status – impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure Long‐Term Registry
  20. IGENDA protocol
  21. Women-specific predictors of cardiovascular disease risk - new paradigms
  22. Metabolomic fingerprint of coronary blood in STEMI patients depends on the ischemic time and inflammatory state
  23. Gender differences in cardiology
  24. Chemotherapy-induced cardiotoxicity
  25. Metabolomic Approach to Redox and Nitrosative Reactions in Cardiovascular Diseases
  26. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry
  27. The need of a gender-corrected evidence based medicine
  28. Early right ventricular dysfunction in highly selected (totally free from cardiovascular risk factors and other comorbidities) human immunodeficiency virus patients: A pilot study with advanced echocardiography
  29. Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects
  30. Looking for the gender equality
  31. Blood metabolomic fingerprint is distinct in healthy coronary and in stenosing or microvascular ischemic heart disease
  32. Distinctive Metabolomic Fingerprint in Scleroderma Patients with Pulmonary Arterial Hypertension
  33. Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
  34. Metabolomics and Cardiology: Toward the Path of Perinatal Programming and Personalized Medicine
  35. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy
  36. "Omics" sciences in antiblastic cardiotoxicity and cardioprotection
  37. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients
  38. Metabolomic applications in cardiology
  39. A New Type of Physical Activity from an Ancient Tradition: The Sardinian Folk Dance “Ballu Sardu”
  40. Metabolic changes related to different degrees of heart failure
  41. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection
  42. Cardioprotection by gene therapy
  43. Endodontic Infection and Endothelial Dysfunction Are Associated with Different Mechanisms in Men and Women
  44. Heart rate variability shows different cardiovascular modulation in Parkinson’s disease patients with tremor dominant subtype compared to those with akinetic rigid dominant subtype
  45. Effects of an Aquatic-Based Exercise Program to Improve Cardiometabolic Profile, Quality of Life, and Physical Activity Levels in Men With Type 2 Diabetes Mellitus
  46. Contractile reserve in systemic sclerosis patients as a major predictor of global cardiac impairment and exercise tolerance
  47. Sex differences in congenital heart defects and genetically induced arrhythmias
  48. Altered Transmural Contractility in Postmenopausal Women Affected by Cardiac Syndrome X
  49. Ankle–Brachial Index and Its Link to Automated Carotid Ultrasound Measurement of Intima–Media Thickness Variability in 500 Japanese Coronary Artery Disease Patients
  50. Effects of metformin and exercise training, alone or in association, on cardio-pulmonary performance and quality of life in insulin resistance patients
  51. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry
  52. Subclinical contractility impairment in HIV-infected patients: Dependence on the class of antiretroviral drugs
  53. Relationship between high values of HOMA-IR and cardiovascular response to metformin
  54. Association of automated carotid IMT measurement and HbA1c in Japanese patients with coronary artery disease
  55. Early impairment of contractility reserve in patients with insulin resistance in comparison with healthy subjects
  56. Metabolomic approach to foetal and neonatal heart
  57. Could ADMA levels in young adults born preterm predict an early endothelial dysfunction?
  58. Cardiopulmonary and endothelial effects of metformin treatment in an insulin resistant population
  59. Association of Endodontic Infection with Detection of an Initial Lesion to the Cardiovascular System
  60. A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics
  61. Metabolomics
  62. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction
  63. Inverted Takotsubo Cardiomyopathy Induced by Dobutamine Stress Echocardiography with Atypical Presentation
  64. Cardiovascular modulation during vagus nerve stimulation therapy in patients with refractory epilepsy
  65. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment
  66. Gender determinants of cardiovascular risk factors and diseases
  67. Echocardiographic accidental finding of asymptomatic cardiac and pulmonary embolism caused by cement leakage after percutaneous vertebroplasty
  68. Cardiac effects of l-thyroxine administration in borderline hypothyroidism
  69. Effect of Hormone Therapy on Exercise Capacity in Early Postmenopausal Women
  70. Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers
  71. Impairment of physical exercise capacity in healthy postmenopausal women
  72. Cardiac function in borderline hypothyroidism: a study by pulsed wave tissue Doppler imaging
  73. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk